Highlights of This Issue  5831

SPECIAL FEATURES

Editorial  5833
Gauging Progress in a Decades-Old Fight
Jesse Potash and Kenneth C. Anderson

CCR Translations  5834
Model T Muscle CARs Can Treat Brain Tumors
Laura A. Johnson
See article p. 5949

CCR New Strategies  5837
New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents
Katherine A. Janeway and Robert G. Maki

CCR Perspectives in Drug Approval  5845
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

Molecular Pathways  5850
Molecular Pathways: Tumor Cells Co-opt the Brain-Specific Metabolism Gene CPT1C to Promote Survival
Patrick T. Reilly and Tak W. Mak

Review  5856
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Brian M. Slomovitz and Robert L. Coleman

HUMAN CANCER BIOLOGY  5865
Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis
Carolyn D. Hurst, Fiona M. Platt, Claire F. Taylor, and Margaret A. Knowles

Functional, Genetic, and Epigenetic Aspects of Base and Nucleotide Excision Repair in Colorectal Carcinomas

5888
Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells
Shahriar Koochekpour, Sunipa Majumdar, Gissou Azabdaftari, Kristopher Attwood, Ray Scioneaux, Dhatthayani Subramani, Charles Manhardt, Giovanni D. Lorusso, Stacey S. Willard, Hillary Thompson, Mojgan Shourideh, Katayoon Rezaei, Oliver Sartor, James L. Mohler, and Robert L. Vessella

5902
Expression of Serotonin Receptors in Human Hepatocellular Cancer
Christopher Soll, Marc-Olivier Riener, Christian Eugen Oberkofler, Claus Hellerbrand, Peter J. Wild, Michelle L. DeOliveira, and Pierre-Alain Clavien
CANCER THERAPY: PRECLINICAL

5911  Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo
Fiona Simpkins, Pedro Hevia-Paez, Jun Sun, Wendy Ullmer, Candace A. Gilbert, Thiago da Silva, Ali Pedram, Ellis R. Levin, Isuldinha M. Reis, Brian Rabinovich, Diana Azzam, Xiang-Xi Xu, Tan A. Ince, Ji-Yeon Yang, Roel G.W. Verhaak, Yiling Lu, Gordon B. Mills, and Joyce M. Sliferland

5924  Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status
Maria Joao Baptista, Ana Muntañola, Eva Calpe, Pau Abrissqueta, Olga Salamero, Eva Fernández, Carles Codony, Eva Giné, Susana G. Kalko, Marta Crespo, and Francesc Bosch

5934  Stichoposide C Induces Apoptosis through the Generation of Ceramide in Leukemia and Colorectal Cancer Cells and Shows In Vivo Antitumor Activity
Seong-Hoon Yun, Eun-Seon Park, Sung-Won Shin, Yong-Woo Na, Jin-Young Han, Jin-Sook Jeong, Valeria V. Shastina, Valentin A. Stonik, Joo-In Park, and Jong-Young Kwak

5949  Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
See commentary p. 5834

5961  FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51
Nu Zhang, Xinjian Wu, Lixuan Yang, Feizhe Xiao, Heng Zhang, Aidong Zhou, Zhengqiong Huang, and Suyun Huang

IMAGING, DIAGNOSIS, PROGNOSIS

5972  Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer
Dharamja Madhavan, Manuel Dacknick, Markus Wallwiener, Katarina Cuk, Caroline Modugno, Martina Schapp, Sarah Schott, Jörg Heil, Andrey Turchinovich, Rongxi Yang, Axel Benner, Sabine Rietdorf, Andreas Trumpp, Christof Sihn, Klaus Pantel, Andreas Schmeeisweiss, and Barbara Burwinkel

5983  Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study
Xia Pu, Yuanying Ye, Margaret R. Spitz, Liang Wang, Jian Gu, Scott M. Lippman, Michelle A.T. Hildebrandt, Wun Ki Hong, John D. Minna, Jack A. Roth, Ping Yang, and Xifeng Wu

5992  Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage I/II Gastric Cancer
Masanori Terashima, Koji Kitada, Atsushi Ochiai, Wataru Ichikawa, Issei Kurahashi, Shinichi Sakuramoto, Hirotaka Katai, Tatsuki Sano, Hiroshi Inamura, and Mitsu Okada; for the ACTS-GC Group

6001  ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients
Anita Sven, Trude H. Aagesen, Arild Nesbakken, Gunn Iren Meling, Torleiv O. Rognum, Knut Liestol, Rolf I. Skotheim, and Ragnhild A. Lothe

CANCER THERAPY: CLINICAL

6011  A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children’s Oncology Group Phase I Consortium Report
Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stempak, Frank M. Balis, and Susan M. Blaney
Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer

Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors
Yan Xin, Jessica Li, Jenny Wu, Rashell Kinard, Colin D. Weekes, Amita Patnaik, Patricia LoRusso, Rainer Brachmann, Raymond K. Tong, Yibing Yan, Ryan Watts, Shuang Bai, and Priti S. Hegde

Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)
Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, Lukas Bubendorf, Rolf Jaggli, Daniel C. Betticher, Peter Brauchli, Denise Cotting, Cornelia Droega, Ralph Winterhalder, Daniele Siciliano, Dominik R. Berthold, Miklos Pless, Ralph Schiess, Roger von Moos, and Silke Gillessen; for the Swiss Group for Clinical Cancer Research (SAKK)

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine
Shigeyuki Matsui, Richard Simon, Pingping Qu, John D. Shaughnessy Jr, Bart Barlogie, and John Crowley

LETTERS TO THE EDITOR

Spleen Cells from Young Donors Eradicate Large Tumors—Letter
Laszlo Radvanyi

Spleen Cells from Young Donors Eradicate Large Tumors—Response
Donald A. Rowley, Karin Schreiber, and Hans Schreiber

Bioluminescence Imaging of Prenylation Inhibition—Letter
Philippe Clezardin

Bioluminescence Imaging of Prenylation Inhibition—Response
Kendall J. Blumer, Katherine Weilbaecher, and David Piwnica-Worms

CORRECTION

Correction: The Use of Quantitative Real-Time Reverse-Transcriptase PCR for 5' and 3' Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

The Journal of Clinical and Translational Research v www.aacrjournals.org
ABOUT THE COVER

Serotonin receptors are expressed in the liver and human hepatocellular cancer (HCC). The cover shows the immunohistochemical staining of the serotonin receptor 1B (HTR1B) in a specimen of human HCC. In a subset of tumors, the expression of HTR1B was significantly increased compared with corresponding nontumor liver tissue of the same patient. The expression of the receptor correlated with a higher proliferation rate and tumor size, suggesting an involvement of serotonin receptors in tumor growth of human HCC. For details, see the article by Soll and colleagues on page 5902 of this issue.